A clinical trial involving liraglutide was updated on September 10, 2026. Registered as NCT06836284, the study is titled "The Evira Study: Additional Support During Obesity Treatment." Its current status is listed as recruiting. The trial phase is designated as not applicable. Liraglutide remains an approved compound, and this update reflects its inclusion in ongoing clinical research related to obesity treatment support.
No results or outcome data have been reported for this trial at this stage. The listing indicates only that recruitment is underway and that the study is registered under the identifier NCT06836284. Details regarding trial design, participant criteria, or endpoints beyond the title and status were not provided in this update.
Readers interested in tracking this trial can refer to its registry listing for further status changes as they become available. This brief reflects only the information published in the trial record as of the stated date and does not include any additional findings, safety data, or efficacy claims. For more background on liraglutide, readers can consult the compound overview.